IBI355 clinical trials
Also written IBI355.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses IBI355 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IBI355
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses IBI355 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Tolerability of IBI355 in Patients With Primary Sjogren's SyndromeCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT06484855Written as IBI355
- Safety and Tolerability of IBI355 in Healthy VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT06416787Written as IBI355
- Safety and Tolerance Study of IBI355 in Health VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT06110338Written as IBI355